Overview

• Peer-reviewed findings in Science Translational Medicine report serial sampling over four months from two recurrent cases treated with intratumoral CAN-3110, yielding roughly 96–97 biopsy cores.
• Comprehensive profiling—spatial CyCIF, single-cell RNA sequencing, proteomics, phosphoproteomics, immunopeptidomics, T cell clonotype analysis, and AI-enabled pathology—captured time-resolved tumor changes.
• Analyses showed microenvironment reshaping and immune activation, including expansion of tissue-resident memory T cell clonotypes and HLA-presented peptides, despite MRI suggesting progression consistent with pseudoprogression.
• Clinically, one patient had a pathologic response and the other maintained stable disease, and investigators are continuing accrual targeting 12 patients with plans to extend the platform to additional vaccine immunotherapies.
• A multi-institutional team funded in part by Break Through Cancer led the effort and disclosed conflicts of interest, including related oncolytic HSV1 intellectual property and advisory roles for senior investigators.